Absci Corporation, a generative AI drug creation company, is advancing its AI-designed drugs into clinical trials. Founded 15 years ago, Absci shifted focus to AI-driven drug discovery in 2018, targeting difficult proteins like GPCRs and ion channels. The company expects two Phase II clinical trial results within 24 months for treatments addressing androgenetic alopecia (hair loss) and endometriosis. Absci highlights its cost-efficient drug development, bringing drugs to clinic for $10-15 million compared to traditional $50+ million, enabling faster failure and iteration in drug discovery.
On World Elder Abuse Awareness Day, First Federal Savings Bank and the Independent Community Bankers of America (ICBA) raised awareness about elder financial abuse, which involves billions in suspected losses annually. They shared practical tips to p...
Castellum Inc. shares surged 51% in premarket trading after the company secured a $250 million contract with the U.S. Navy to provide logistics IT services. This multi-year indefinite delivery/indefinite quantity contract strengthens Castellum's posi...
Direxion CEO Douglas Yones cautions that SpaceX's valuation, despite being the largest IPO ever, is largely driven by investor sentiment rather than solid financial fundamentals. The excitement is fueled by SpaceX's scale, Elon Musk's leadership, and...
Cuprina Holdings' stock jumped 64.73% last Friday after the company announced it had regained compliance with Nasdaq Capital Market listing requirements, avoiding delisting. This compliance was achieved after an appeal following a prior notice of non...
IperionX has agreed to acquire mining and processing assets from Covia Solutions adjacent to its Titan Project in Tennessee for $3 million. This acquisition adds mineral rights, stockpiles, equipment, and infrastructure, enhancing IperionX's position...
